Aurobindo Pharma Share Price: Duty Reforms ka Kamaal, Brokerage ne ₹1,430 Target Diya!

BROKERAGE-REPORTS
Whalesbook Logo
AuthorRiya Kapoor|Published at:
Aurobindo Pharma Share Price: Duty Reforms ka Kamaal, Brokerage ne ₹1,430 Target Diya!
Overview

Aurobindo Pharma ke liye ekdum solid update hai! Government ne important intermediates par import duties kam kar di hain, jisse company ka EBITDA aane wale saal mein **₹5.5 se ₹6.6 billion** tak badh sakta hai. Isi wajah se, Motilal Oswal ne 'BUY' rating ke saath **₹1,430** ka price target maintain kiya hai.

Pharma Sector Ka Boost!

Yaar, yeh jo import duties kam hui hain na, khaas pharma intermediates jaise Pen-g, 6-APA aur amoxicillin sales par, ye Aurobindo Pharma ke liye game changer sabit ho sakti hain. Brokerage ka estimate hai ki isse company ka EBITDA agle 12 mahino mein ₹5.5 billion se lekar ₹6.6 billion tak badh jayega. Company ne apne developed markets ke liye product pipeline ko expand karne aur manufacturing capacity badhane par bhi zor diya hai. US market ke liye company ki ANDA filings kaafi substantial hain.

Regulatory Kaam Aur Future Plans

Abhi Eugia-III facility mein kuch regulatory kaam chal raha hai, jo injectables launch karne ke liye bahut important hai. Company authorities ke saath milkar issues solve karne ki koshish kar rahi hai, jisse products time par market mein aa saken.

Stock Ka Current Scene Aur Competition

Market mein company ka cap lagbhag ₹50,000 crore ke aas paas hai, aur P/E ratio 26.5x ke around. February 1, 2026 ko stock ₹1,055 par close hua tha, aur daily trading volume 6 million shares ke aas paas rehta hai. Iska 52-week range ₹820 se ₹1,250 ke beech raha hai. US jaise highly regulated markets mein Sun Pharma, Cipla, Dr. Reddy's jaise bade players se competition hai.

Sector Ki Taakat Aur Aage Ka Outlook

Waqai, Indian pharma sector ko government ki policies se kaafi support mil raha hai, jaise PLI schemes aur duty adjustments. Isse companies ke liye business karna aasan ho gaya hai. Motilal Oswal ko umeed hai ki FY26 se FY28 ke beech company ka revenue 9%, EBITDA 14%, aur PAT 21% ki CAGR se grow karega. Brokerage ne stock ko uske forward earnings ke 16x par value kiya hai, aur target diya hai ₹1,430. Isi wajah se 'BUY' rating maintain ki gayi hai.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.